Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 19, 2015

View Archived Issues

Stabilization of alpha-crystallins improves lens opacity in cataract models

AbbVie reveals data on new BTK inhibitor

RP-10107, a potent glutaminase inhibitor

Novel anti-FOLR1 MAb KHK-2805 for ovarian cancer

Preclinical and clinical results of SM-04690 for the treatment of osteoarthritis

Collaborative research agreement to analyze novel anticancer agents by MSI

Immune responses seen with DNA-based vaccine INO-3112 in head and neck squamous cell carcinoma

Symic selects SB-061 as first osteoarthritis clinical candidate

Amylyx Pharmaceuticals receives funding to develop drug combination for ALS

Radius Health submits MAA for abaloparatide for postmenopausal osteoporosis

Phase III DUO study of duvelisib in CLL reaches target enrollment

Merck KGaA and Pfizer receive FDA breakthrough therapy designation for avelumab

Phylogica identifies new candidates that block intracellular MYC activity

Femtogenix discloses antineoplastic compounds

Kyungpook National University (KNU) and KNU Hospital patent PDK4 inhibitors

DTRM Biopharma patents BTK inhibitors

Medshine Discovery introduces ROCK inhibitors

Bayer Schering Pharma presents sGC activators

UM Pharmauji and Aurigene Discovery Technologies divulge DHODH inhibitors

Repurposed antihypertensive agent shows promise for Huntington's disease

Launch of pan-European MoTriColor consortium for colorectal cancer

First FDA approval of naloxone nasal spray for opioid overdose

Servier exercises licensing option with Cellectis for UCART-19

New company Vertice Pharma to acquire VistaPharm

Codiak BioSciences launched to develop exosome-based therapeutics and diagnostics

Aerpio reports full results from phase IIa trial of AKB-9778 in DME

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...